UKMF

Past Meetings

• 14 Mar 2018 — Scientific Workshop 14 March 2018[ + ]

  The theme for the UKMF Scientific Workshop was Immunotherapy and the Myeloma Microenvironment and took place on Wednesday 14th March 2018 at the Cavendish Conference Centre, London.

  The Michael Morley lecture was brilliantly presented by Dr Niels van de Donk from the  VU University Medical Centre in Amsterdam. He presented a talk on ‘The effects of Daratumumab on plasma cells and other elements of the microenvironment’.

  A full programme can be downloaded below. Thank you once again to our generous sponsors.

  Available talks can be downloaded here.

   

  • Scientific Workshop Programme — Dr Andy Chantry
  • The importance of the tumour microenvironment in multiple myeloma — Dr Claire Edwards
  • Myeloma Rudy- current progress and next steps for patients, patient groups, clinicians and researchers — Dr Kassim Javaid
  • Investigating the bone marrow microenvironment in MGUS and multiple myeloma - evidence for early and irreversible transformation — Dr Dan Tennant
  • Mitochondria Are Transferred from Non-Malignant Stroma Cells to Malignant Plasma Cells, Via Tunnelling Nanotubes in a CD38 Dependent Mechanism, a Process That Promotes Myeloma. — Chris Marlein
  • The use of oncolytic virus therapy for myeloma shows considerable promise in pre-clinical models — Georgia Stewart
  • HUWE1 inhibition as a therapeutic strategy to target MYC in MM — Lisa Crawford
• 09 Nov 2017 — Autumn Day 2017[ + ]

  The theme for the Autumn Day meeting at SOAS on 9th November 2017 was ‘The problem with proteins and immunity’. 

  The Michael Morley lecture was presented by Dr Madhave Dhodapka, Yale University on ‘Immune environment in MGUS and multiple myeloma’.

  A full programme can be downloaded below as well as most of the talks from the day. Unfortunately, we are unable to share the presentations from Dr Dhodapka and David Thompson.

   

   

   

  • Autumn Day Programme — John Ashcroft
  • Science — Christopher Parrish
  • 18FDG-PET positivity post radiotherapy is a biomarker Dr Faye for relapse in patients with plasmacytoma — Faye Sharpley
  • Identifying ultra-high risk myeloma by integrated molecular genetic and gene expression profiling — Amy Sherborne
  • Potential toxicities and clinical issues with immunotherapies — Reuben Benjamin
  • Clinical profiles in the AL-Chemy study: a single centre prospective observational study of 1203 patients diagnosed with systemic AL amyloidosis at the UK National Amyloidosis Centre (UK NAC) — Richa Manwani
  • Immunotherapies in myeloma, where are we today? — Prof Gordon Cook & Christopher Parrish
• 03 Aug 2017 — 1st Oxford Myeloma Workshop[ + ]

  Outside of the International Myeloma workshop we lack a comprehensive educational meeting on plasma cells disorders. With significant developments in scientific understanding, diagnostic testing and guidelines, prognostication, treatment principles and treatment options there is considerable knowledge in the area of plasma cell disorders that has to be disseminated.

  As an individual interested in the field of plasma cell disorders, you would be in agreement that the last 2-3 years have seen a step change in both scientific developments, paralleled by a substantial transformation in therapeutics available in myeloma. There could not be an apposite time for us to educate and engage those working in this field.

  We are excited to put together a comprehensive workshop programme to cover all aspects of plasma cell disorders. We have a brilliant faculty both from UK as well Europe and USA, who are well respected in the field of plasma cell disorders. The course is aimed at a cross-section of haematology trainees, haematology consultants, scientists working in the field of myeloma as well as allied nursing and pharmacy colleagues.

  The First Oxford Myeloma Workshop will be held at  St Catherine’s College, Oxford, on 3rd and 4th August 2017.

  We would be delighted if you can attend this workshop. On this website we have a detailed programme, list of speakers and details of registration for the meeting. We look forward to meeting you in August, and hope that you will also have time to explore our beautiful, historic city.

   

  Dr Karthik Ramasamy          Prof Udo Oppermann           Dr Jaimal Kothari

  • 1st Oxford Myeloma Workshop — Dr Karthik Ramasamy
• 22 Mar 2017 — UKMF Spring Day 2017[ + ]

  The theme for the UKMF Spring Day will be, Personalised therapy in myeloma: Fact or Fiction? 

  • Michael Morley Lecture:  Understanding the myeloma environment by Irene Ghobrial                                                                          
  •  Patients Case histories
  • Topics: Driver mutations, MRD testing, Hevylite assays, Frailty biomarkers
  • Biomarkers for personalised therapy in Myeloma
  • ASH Bursary winners
  • Eric Low – tribute to former Myeloma UK Chief Executive

  If you would like to register for this event, please visit http://www.hartleytaylor.co.uk or contact Wendy@ukmf.org.uk

  • Spring Day Programme — UKMF
  • Making sense of prognostic factors — Dean Smith
  • Actionable/driver mutations in myeloma — Mike Chapman
  • Hevylite assays de-convoluted — Karthik Ramasamy
  • MRD testing:which platforms, which patients? — Roger Owen
  • The patient's perspective — Eric Low
  • Frailty Biomarkers — Prof Gordon Cook
• 09 Nov 2016 — UKMF Autumn Day 2016[ + ]

   

  The theme for the UKMF Autumn Day on 9th November 2016 was ‘Next Generation Therapies in Myeloma’.

  We were delighted to welcome Prof Sagar Lonial (Atlanta, USA), who presented the Michael Morley lecture on ‘Treatment of Myeloma with monoclonal antibodies’is open for registration.

   

  Talks can be downloaded below.

   

  • Autumn Day Programme 9th November 2016 — Karthik Ramasamy
  • Treatment of myeloma with monoclonal antibodies — Prof Sagar Lonial
  • New Proteasome inhibitors in myeloma — Dr Holger Auner
  • NICE guidance MM - practice implications — Dr Guy Pratt
  • What is high risk myeloma? Challenging case studies — Dr Ceri Bygrave
  • Challenging cases - double refractory MM and clinical overview of anti CD38 monoclonal antibodies — Dr Rachel Hall
  • Immunotherapy in myeloma, where do we go? — Prof Paul Moss
  • New agents in MM presenting / relapsing with renal impairmen — Karthik Ramasamy
• 20 Apr 2016 — BSH/ UKMF Symposium – April 2016, Glasgow[ + ]

  The BSH/ UKMF joint symposium at the SECC in Glasgow in April 2016 was a huge success. The theme for the symposium, was ‘Understanding Risk in Myeloma: A practical approach’.  Prof Kwee Yong and Dr Karthik Ramasamy were the session Chairs. Guest international speakers included, Phillipe Moreau (France), Sonja Sweegman (The Netherlands) and Wee Joo Chng (Singapore).

  

  

  • Risk Stratification in the older patient; what are our priorities — Dr Sonja Sweegman
  • Integrating NGS approaches into patient care: How I manage high-risk disease at presentation in a transplant eligible patient — Prof Chung Wee Joo
  • High-risk smoldering myeloma — Philippe Moreau
• 17 Mar 2016 — UKMF Spring Day 2016[ + ]

  The Spring Day had a record turn out. Talks will be available to download from this site.

  Special thanks to all our guest speakers, especially to Dr Peter Croucher, who flew from Australia to give an excellent talk on Mechanisms of bone loss in Multiple Myeloma: an increasingly important role for bone cells.

  

  • UKMF Spring Day Programme 17th March 2016 — Jenny Bird
  • Challenging Cases — Dr Neil Rabin
  • Evidence for use of CT scanning and PET-CT in managing patients with Myeloma — Dr Elena Zamagni
  • Quantitative whole-body MRI for treatment response monitoring in Multiple Myeloma — Dr Arash Latifoltojar
  • Exercise and Physiotherapy in Myeloma — Orla McCourt
  • Osteonecrosis of the jaws — Stefano Fedele
  • Bone Pain: A Practical Approach to Management — Dr Rowan Hearn
• 04 Nov 2015 — UKMF Autumn Day 2015[ + ]

  Thank you to everyone who attended this meeting. We are grateful to our sponsors and delegates and by the numbers and feedback, we are delighted that this event was a huge success.

  The theme for this meeting was ‘Myeloma: The Challenge of Communicating Complex Data’.

  The Michael Morley lecture will be presented by Prof. Faith Davies from the University of Arkansas.

  The registration fee for the UKMF Spring and Autumn Days are £60. There is a discount fee of £40 available for scientists and nurses.

  A copy of the programme can be downloaded below.

  To register on line, click here http://www.hartleytaylor-registration.co.uk/hartley/registration.aspx?id=UKM1

  • Autumn Day 2015 Programme — Roger Owen
  • Frailty, salvage ASCT and AlloSCT: — Prof Gordon Cook
  • What is the most effective method of preventing bone disease in patients with myeloma? — Guy Pratt
  • Hierarchical Cluster analysis of Florescent in Situ Hybridisation in newly diagnosed myeloma patients — Ieuan Walker
  • Guidelines for the correct determination of second primary malignancies (SPM) in myeloma trails — John Jones
  • Lisa Crawford — The E3 ligase HUWE1 is a potential therapeutic target in Multiple Myeloma
  • Pomalidomide Talk — Nicola Maciocia
  • Bleeding diathesis, thrombotic tendencies and endothelial dysfunction in systemic AL patients — Shameem Mahmood
  • Bendamustine therapy in MM — Karthik Ramasamy
• 19 Mar 2015 — UKMF Spring Day 2015[ + ]

  The UKMF Spring Day was held on 19th March 2015 at SOAS, central London. A copy of the programme and most of the talks can be downloaded below.

  Thank you to all the UKMF sponsors for their continued support.

   

  UKMF Chair, Dr Jenny Bird with international guest speakers, Prof Keith Stewart and Dr Ramon Garcia-Sanz

  • UKMF Spring Day 15 Programme — Prof Graham Jackson
  • Genomic Guided Therapy in Myeloma — Prof Keith Stewart
  • Minimal residual disease in multiple myeloma by next generation sequencing — Dr Ramon Garcia-Sanz
  • Paraproteins and response assessments - – what have we learnt from MRC trials? — Prof Mark Drayson
  • multiple myeloma: D-type cyclin and PI3k pathways — Prof Kwee Yong
  • MRD in myeloma — Dr Roger Owen
  • The extent of intra-clonal genetic diversity within the myeloma clone is a predictive biomarker of progression and outcome after treatment — Dr Lorenzo Melchor
  • Flow-cytometric quantification of minimal residual disease (MRD) in myeloma: independent outcome prediction & sequential survival benefits per log tumour reduction — Dr Andy Rawstron
  • Targeting RAS pathways in myeloma — Dr Martin Kaiser
• 12 Nov 2014 — Autumn Day 2014[ + ]

  The theme for the 2014 Autumn day was ‘New developments in Myeloma’.

  We were delighted to announce a full programme with the Michael Morley guest speaker from the Mayo clinic, Professor Angela Dispenzieri, who presented a lecture entitled, “Benign monoclonal gammoapthy. How benign is it really?”

  Please see programme for more information.

  Nearly 200 delegates attended, making this the most successful UKMF Autumn Day yet.

  

  Here is the UKMF Chair, Dr Jenny Bird presenting a certificate to the Michael Morley guest speaker, Dr Angela Dispenzieri at the Autumn Day 2014.

   

   

  • UKMF Autumn Day Programme Nov 2014 — Guy Pratt
  • Benign monocional gammopathy: how benign is it really? — Prof Angela Dispenzieri
  • The place of newer imaging techniques in multiple myeloma — Dr Andrew Chantry
  • Stem Cell Transplantation in Myeloma — Prof Gordon Cook
  • Genetic subtyping of Myeloma — Dr Martin Kaiser
  • How to manage high risk myeloma — Dr Matthew Jenner
  • Management of Myeloma Spinal Disease — Mr Sean Malloy
  • A Pomalidomide Update — Dr Matthew Streetly